|
|
||||||||
1 Department of Pharmacology and Toxicology, Wright State University School of Medicine, Dayton, Ohio 45401; 2 Department of Medicine, Duke University, Winston-Salem; and Veterans Affairs Medical Center, Durham, North Carolina 27705
| |
ABSTRACT |
|---|
|
|
|---|
The objective was to determine the central nervous system (CNS) responses to dehydration (c-Fos and vasopressin mRNA) in mice lacking the ANG AT1a receptor [ANG AT1a knockout (KO)]. Control and AT1a KO mice were dehydrated for 24 or 48 h. Baseline plasma vasopressin (VP) was not different between the groups; however, the response to dehydration was attenuated in AT1a KO (24 ± 11 vs. 10.6 ± 2.7 pg/ml). Dehydration produced similar increases in plasma osmolality and depletion of posterior pituitary VP content. Neuronal activation was observed as increases in c-Fos protein and VP mRNA. The supraoptic responses were not different between groups. In the paraventricular nucleus (PVN), c-Fos-positive neurons (57.4 ± 10.7 vs. 98.4 ± 7.4 c-Fos cells/PVN, control vs. AT1a KO) and VP mRNA levels (1.0 ± 0.1 vs. 1.4 ± 0.1 µCi, control vs. AT1a KO) were increased with greater responses in AT1a KO. A comparison of 1- to 2-day water deprivation showed that plasma VP, brain c-Fos, and VP mRNA returned toward control on day 2, although plasma osmolality remained high. Data demonstrate that AT1a KO mice show a dichotomous response to dehydration, reduced for plasma VP and enhanced for PVN c-Fos protein and VP mRNA. The results illustrate the importance of ANG AT1a receptors in the regulation of osmotic and endocrine balance.
central nervous system; hypothalamus; water balance; blood pressure; molecular genetics; knockout models; paraventricular nucleus
| |
INTRODUCTION |
|---|
|
|
|---|
THERE ARE STRONG LINKS between the central ANG II and vasopressin (VP) systems. ANG II activates VP neurons, as seen by neuronal firing, c-Fos and VP mRNA expression, and VP secretion (6, 8, 23, 24, 26, 35). ANG peptides and their receptors are present in the neurosecretory, paraventricular (PVN), and supraoptic nuclei (SON), and in brain regions that are osmosensitive (13, 15). A recent study found a similar distribution pattern for ANG-(1-7), VP, and colocalization in a subpopulation of PVN neurons (15). Alterations in fluid balance produced by dehydration or salt loading result in increases in central nervous system (CNS) ANG receptors, ANG AT1a receptor mRNA, and VP mRNA (2, 3, 20, 27, 37, 39, 40).
ANG receptors are differentiated into AT1 and AT2 subtypes with the ANG AT1a receptor clearly associated with CNS, vascular, and endocrine effects. Pharmacological antagonists to the AT1 receptor are used clinically for the treatment of hypertension and cardiac failure and as tools for the study of pharmacological action. There is evidence that the AT1 antagonists block the pressor, endocrine, and cellular responses to ANG II stimulation (7). However, when ANG AT1 antagonists were tested against physiological stimulation, certain questions and controversies emerged. For example, losartan, an AT1 antagonist, was much less effective than ANG AT2 antagonists in blocking the drinking response to dehydration (17, 38). Studies in animals lacking vasopressin suggested that neither AT1 nor AT2 receptors were involved in the response to dehydration (44). Additionally, losartan was not effective in blocking the plasma VP response to hemorrhage (33). Questions have been raised concerning the specificity of losartan and the possibility of other central ANG receptor subtypes (9, 29, 46).
A new method that is useful for the study of functionality is gene deletion or knockout models. The premise is that the removal of an essential receptor protein and subsequent evaluation of phenotypic expression and physiological responses will, by inference, provide information on function. An advantage of gene deletion models is that the absence of the specific protein means that the blockade resulting from the receptor loss should be complete. This is in contrast to protocols that rely on pharmacological antagonism, in which drug concentrations and tissue levels are constantly changing and specificity may be a question. The drawback to genetic knockout models is that the protein of interest is removed from conception onward. Thus development proceeds in its absence, which may produce secondary changes or compensatory effects. However, at least in the AT1a KO, there is no evidence for changes (upregulation) of other ANG receptor subtypes (27). Published reports suggest that the AT1a KO model is useful for studying physiological genomics, because the basic phenotypic characteristics are compatible with the known functions of the AT1a receptor: reduced blood pressure, increased drinking, and reduced urine osmolality (12, 31, 41). However, investigations have just begun to tap the utility of the model for studying the role of ANG AT1a receptors in basic neuronal and endocrine physiology.
The AT1a KO strain provides a unique model for the study of angiotensinergic control of the VP axis. Investigation of the neurosecretory system under basal and osmotically stimulated conditions will provide clues as to the role of the peptide and its receptor in endocrine and osmotic balance. We hypothesize that if ANG AT1a receptors are essential to VP neuronal function and osmotic responsiveness, that these will be attenuated in the absence of the receptor. Dehydration is used as the stimulus with evaluation of VP secretion and storage and activation of central osmosentive regions, PVN, SON, subfornical organ (SFO), and median preoptic (MnPO) using c-Fos and VP mRNA.
| |
METHODS |
|---|
|
|
|---|
Animals.
Male mice lacking ANG AT1a receptors were bred and
maintained in the animal facility of the Durham Veterans Affairs
Medical Center. The mice were F2 progeny derived from
crosses of (129×C57Bl/6) F1 AT+/
parents.
This F2 generation of AT+/+ and AT
/
possesses similar random assortment of background genes making it an
appropriate match for study. ANG AT1a genotypes were
determined by Southern blot analysis of DNA isolated from tail biopsies
(12). The animals were housed singly with free access to
water and food.
Protocol. Six groups of animals were studied: AT1A KO and their controls with water ad libitum or after 24 or 48 h of water deprivation. The average body weights for the groups were 33.5 ± 1.7 vs. 35.1 ± 1.3 g (control vs. AT1a KO, respectively). The mice were anesthetized with pentobarbital sodium (50 mg/kg ip) and rapidly decapitated. Brains were collected in fixative (Bouin's solution); posterior pituitaries were frozen on dry ice, and trunk blood was collected on ice in heparinized tubes.
RIA and osmolality. Plasma was separated for measurement of osmolality by freezing point depression (20 µl) and of VP by RIA. For RIA, plasma samples (100-200 µl) were extracted with acetone and petroleum ether. The lyophilized extract was resuspended in assay buffer, and VP concentrations were measured using a specific and sensitive assay. The ED50 for the VP assay is 4-5 pg/tube. Preliminary studies showed that baseline plasma levels were similar in conscious or pentobarbital sodium-anesthetized animals. Acid extracts (0.1 N HCl) of posterior pituitaries were diluted, and VP was measured by RIA.
Immunohistochemistry and in situ hybridization. Brains were fixed by immersion in Bouin's solution containing 20% sucrose for 4 days at 4°C. Series of 20-µm cryostat sections (1 in 5) were collected in 0.01 M PBS. Sections were processed for Nissl (general histology), c-Fos, VP, and VP mRNA. The immunostaining protocol used 48-h antisera incubation followed by the peroxidase-3-3'diamino benzidine enhanced with nickel (Vectastain Elite, Vector Labs, Burlingame, CA). The rabbit c-Fos antisera was provided by P.J. Larson and J. Mikkelsen (Panum Institute, Denmark) and used at a dilution of 1:50,000. It was made against the NH2-terminal region of synthetic human c-Fos protein (residues 4-17) and cross-reacts with both mouse and rat c-Fos (16). The rabbit VP antiserum was made against VP-neurophysin and used at a dilution of 1:100,000 (NP 818, A. Robinson, University of California at Los Angeles, Los Angeles, CA). For quantifying, we used an image analysis system that combines captured video images (Optronics-DEI 750 D, charge-coupled device camera, Optronics Engineering, Goleta, CA) with image analysis software (MetaMorph Imaging System, West Chester, PA). The numbers of c-Fos-positive neurons within the areas of interest, PVN, SON, MnPO, and rostral forebrain were measured. For the SON and PVN, c-Fos was measured in magnocellular neurons located in the midregion of the nuclei.
The in situ hybridization method for VP mRNA used an oligonucleotide probe as previously described (37). The 30-base pair oligonucleotide is complementary to exon C of vasopressin prohormone mRNA (GIBCO BRL Custom Primers, Rockville, MD). The sequence is GGTGAGGCGGAAAAAACCGTCGTGGCACTC. The probe was labeled with [35S]dATP using 3'-terminal deoxynucleotidyl transferase (Boehringer Mannheim Biochemicals, Indianapolis, IN) and purified using a Nensorb column (DuPont, Boston, MA). The tissue sections were mounted on coated slides (UltraStick, Fisher, Pittsburgh, PA) and air-dried. After being washed in PBS (0.1 M, pH 7.2) and 2× SSC, the labeled probe (~0.4 × 106 cpm/100 µl) was added directly to the tissues. The slides were incubated overnight at 37°C in a humidified chamber and washed sequentially in 1× SSC (1 h at room temperature), 0.5× SSC (1 h at room temperature) and 0.5× SSC (1 h at 50°C). For quantification of the hybridization signal, we used a direct radioactive capture method (Fuji FLA-200, Fuji, Stamford, CT). After air drying, the slides and [14C] standards (ARC, St. Louis, MO) were placed in a Fuji cassette (BAS III). After the appropriate exposure time (7 days for this study), the imaging plate was scanned and the digitized image measured. The amount of radioactivity is proportional to photostimulated luminescence (PSL), which can be quantified with the 14C standards. The intensity of PSL within the midregion of the PVN or SON provides an index of the labeling and mRNA levels. The method is superior to film densitometry that has a more limited range. Figure 1 shows an example of the digitized brain images and the 14C standards. There is clear resolution of the label within the PVN and SON. The PSL within the brain regions is translated into microcuries using the 14C standard curve (R2 = 0.989).
|
Statistical analysis. The data are presented as the means ± SE. ANOVA for multiple groups was used to determine significance (P < 0.05) followed by a Newman-Keuls post hoc comparison.
| |
RESULTS |
|---|
|
|
|---|
Dehydration produced time-dependent changes in plasma VP, with the
highest levels seen after 1 day of water deprivation (Fig. 2). The plasma VP response was markedly
attenuated in the AT1a KO group, even though osmolality was
increased more than 30 mosmol/kgH2O (Fig. 2 and Table
1). However, a comparison of the groups
showed that there was no significant change in the responses for
osmolality or loss in body weight (Table 1). Posterior pituitary VP
content was decreased after dehydration with no differences noted
between the groups (Fig. 3). Levels were
depleted 61 and 59% (control vs. AT1a KO) with no further
decrease noted after 2 days of dehydration.
|
|
|
The neuronal response to osmotic stimulation was accentuated in
AT1a KO mice as seen with both c-Fos and VP mRNA levels.
The difference was specific for the PVN region and not seen in the SON
or MnPO. There was almost a twofold increase in the PVN c-Fos response
in the AT1a KO (Fig. 4).
Figure 5 shows c-Fos
immunoreactive staining in PVN in the various groups. There was no
staining in AT1a KO mice consuming water (Fig.
5A), but a marked increase after 1 day of dehydration in
control (Fig. 5B) and AT1a KO (Fig. 5C) animals. Expression was lower after 2 days of
deprivation (Fig. 5D). Neurons in the SFO, MnPO, and
paraventricular thalamic nucleus (PVA) were also activated after
dehydration (Figs. 4 and 6 and Table
2), although there was no difference
between the pattern of activation between the groups.
|
|
|
|
We also evauated the pattern of hypothalamic VP immunoreactivity to
determine whether removal of the AT1a gene had any effect. There was no change in the pattern of staining in PVN or SON (Fig. 7). Likewise, there was no difference in
VP mRNA levels under basal conditions (Fig.
8). However, there was an increased mRNA response in AT1a KO animals, a change specific for the PVN
(Fig. 5). The in situ hybridization reaction product was measured using a radioactive capture method that provides an accurate means of determining the signal over small brain regions (Fig. 1). A dark-field photomicrograph of emulsion-coated brain sections illustrates the
pattern of changes in PVN (Fig. 9). There
was a marked increase in hybridization signal in the AT1a
KO after 1 day of dehydration (Fig. 9C) compared with
AT1a KO mice consuming water (Fig. 9A), control
dehydrated mice (Fig. 9B), or AT1a KO mice after 2 days of
dehydration (Fig. 9D). There was no difference in
the VP mRNA response in the SON (Table
3).
|
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In gene deletion or knockout animal models, the consequence of loss of a gene product can provide clues as to functionality. In the case of the ANG AT1a receptor, the vascular sequel to gene deletion was as predicted. Removal of the ANG vascular pressor receptor produced hypotension and a lack of ANG II responsiveness (12, 41). The scenario for the VP system was more enigmatic, as seen in the present study that tested the effect of dehydration in AT1a KO mice. Although there is support for a critical role of AT1a receptors in the regulation of the VP axis, there were no alterations in hypothalamic VP anatomy or basal VP secretion in AT1a KO mice. The response was attenuated for plasma VP and enhanced for the CNS, c-Fos, and VP mRNA in dehydrated mice. This Discussion tries to reconcile these findings and to support our conclusion that removal of the ANG AT1a receptor produces a state of increased responsiveness to volume and osmotic changes.
The central organization of the ANG and VP systems shows a tight interrelationship. Within the PVN region there is a dense concentration of AT1 receptors, ANG peptides, and VP neurosecretory neurons (13, 15, 22, 27). The ANG receptors are not located directly on VP neurons, as was shown using double hybridization methods (19). However, there is evidence for ANG release within the PVN; for ANG effects on blood pressure, VP secretion, and neural activation; and for effects of ANG antagonists and ANG AT1 antisense oligonucleotides on PVN function (6, 8, 11, 20, 23, 24, 26, 34). In studies that have used ANG as a central stimulant, the consensus is that ANG is critical in VP neuronal responsiveness.
Gene deletion models provide a new means for the investigation of ANG-VP interactions. Strains have been developed that lack all components of the renin-angiotensin system (RAS), with the advantage that the proteins are absent in all tissues and at all times (4). Initial studies in the ANG AT1a and angiotensinogen (Aogen) knockouts showed that fluid balance was altered after removal of the peptide or its receptor. Oliverio et al. (31) reported an increased urine volume and reduced osmolality under baseline conditions and a deficit in concentrating ability in AT1a KO. They suggested that part of the problem was a structural abnormality in the renal papilla (31).
The Aogen knockout showed high urine excretion, low urine osmolality, and high urinary VP levels (14). The original assumption was that the changes in fluid balance were related to a deficit in VP neurosecretory function. However, our results showed that although hypothalamic ANG receptors were absent, the VP system was intact in AT1a KO mice (27, 31). There were no changes in the hypothalamus, posterior pituitary or plasma compartments under baseline conditions. Likewise, the pattern of VP staining in the neurosecretory cells and regions was identical in the AT1a KO and controls. However, when stimulated by 24 h of water deprivation, the AT1a KO showed a reduced plasma VP response even though posterior pituitary levels were depleted to a similar extent. Oliverio et al. (31) reported no difference in dehydration-induced VP release. However, the high baseline levels of plasma VP (40-50 compared with 3-4 pg/ml) suggest that the VP axis was stimulated. Pharmacological blockade of the ANG AT1 receptors also produced alterations in hemorrhage-induced VP release. The results were different with acute vs. chronic blockade (18, 49). There was an attenuation of VP release with acute losartan treatment as seen with our study, whereas chronic blockade caused an accentuated response.
Further proof that the AT1a KO animals are responsive to the dehydration stimulus is seen in the hypothalamic c-Fos and VP mRNA data. For the VP system, c-Fos and mRNA levels are often used as indexes of secretory activity. c-Fos is a part of the immediate early gene cascade, which occurs with neuronal activation, showing both anatomical and temporal specificity (10). In VP neurons, c-Fos is expressed after dehydration, salt loading, hypovolemia, ANG, and other stimuli (6, 10). Likewise, VP mRNA levels are correlated with cellular activity and increased under similar conditions as c-Fos (2, 23, 28, 37, 40). For c-Fos there was activation in the osmosensitive rostral forebrain regions, SFO and MnPO, in both AT1a KO and controls. This indicates that removal of the AT1a receptor does not abolish cellular activation as would be predicted on the basis of pharmacological studies (7). In the hypothalamus, both c-Fos and VP mRNA levels were increased after dehydration. The response was accentuated in the AT1a KO, specifically within the PVN. Recent studies bear relevance to our results, showing that treatment with converting enzyme inhibitors or AT1 antagonists causes activation of c-Fos in PVN neurons (5, 32). Likewise, chronic central blockade of AT1 receptors produced an increase in the plasma VP response to hemorrhage, suggesting an activation under these conditions (49).
Dehydration results in both volume and osmolality changes, making it difficult to determine whether the enhancement in the AT1a KO is related to hypovolemia, hypertonicity, or a combination. Because renal concentrating ability is reduced in the knockout (31), this might result in an accentuated effect of water deprivation. Although there was no significant difference in body weight loss or plasma osmolality between the groups, there was a trend for an increase in osmolality. Even so, the AT1a KO mice showed a reduced plasma VP response, which suggests a deficit in the secretory cascade. This is in contrast to the CNS changes, which were accentuated in the dehydrated AT1a KO mice. Thus, the lack of ANG AT1 receptors may produce a state of dissociation between the sensory component, particularly that which is connected via the PVN, and the final common pathway.
The CNS and plasma responses showed highest levels after 1 day of dehydration. The parameters returned toward baseline on day 2, although the stimulus (high osmolality) was present. These results differ from those in rats and other species, in which there is long-lasting activation of the neurosecretory neurons. Peptide secretion is maintained, as is the neural activity, after prolonged dehydration or salt loading (37, 43, 45). Likewise, mRNA levels were elevated in rats long after rehydration, when osmolality levels had returned to control (50). The results suggest that the balance between transcriptional activation and secretion is different in mice from other rodents. Perhaps the levels of mRNA are sufficient to maintain secretion, or there is an active negative feedback between the plasma and hypothalamic systems.
The question that arises from this data is how to reconcile the apparent increased osmotic response in AT1a KO mice with reports suggesting that ANG receptors are required for CNS signaling. The strongest case for a requisite role for ANG receptors in neuronal responsiveness comes from studies that test the effect of ANG II. AT1 antagonists normally block the neurophysiological, endocrine, intake, and pressor responses to central ANG II. However, in situations in which fluid balance is altered, the AT1 antagonists are not uniformly effective. For example, the AT2 antagonist completely blocked the response to dehydration while losartan was much less effective (17). ANG antagonists did not alter hemorrhage-induced VP secretion and only partially reduced dehydration-stimulated release (33, 48). However, centrally administered losartan reduced the drinking response to dehydration (36) as well as the drinking, VP, and pressor responses to hypertonic saline injection (25). Neurophysiological studies demonstrate that ANG II has both excitatory and inhibitory effects on PVN neurons (1, 21). The situation is complicated with neurons receiving input from different brain regions that have a variety of peptides and neurotransmitters. One must also consider that in the gene deletion models there may be compensation by other receptor subtypes, such as the AT1b or AT2. Oliverio et al. (30) showed that AT1a KO mice were responsive to ANG II stimulation after blockade with losartan. They suggested that the pressor response was mediated by AT1b receptors. Studies in our laboratory show that AT1b mRNA is present in osmosensitive brain regions in mice but is unresponsive to dehydration (3). However, using autoradiographic binding methods, we found no evidence for the presence of AT1b receptors in the AT1a KO mice and no indication of an upregulation after dehydration (27). A role for AT2 receptors in volume regulation is suggested by studies in which treatment with AT2 antagonists modified the response to salt and ANG stimulation (11, 17, 38, 44). Whether, AT2 or AT1b receptors are involved in the accentuated central responses in the AT1a KO remains to be determined.
Our results suggest that the cascade for ANG-VP interactions is more complicated than previously envisioned. In the whole animal, it is probably not a simple afferent/efferent connection with ANG activating VP neurons and eliciting peptide secretion. The use of a gene deletion model has unmasked an interesting facet of the brain RAS, suggesting that the underlying ANG tone functions as a brake to neuronal osmosensitivity. It also opens the possibility that other ANG peptides and receptors (42, 47) may be important in fluid/electrolyte balance.
| |
ACKNOWLEDGEMENTS |
|---|
The authors appreciate the excellent assistance of B. Wirick and T. MacMillan, supported by the Wright State University School of Medicine Biomedical Fellowship Program and National Heart, Lung, and Blood Institute Grant HL-36771, respectively.
| |
FOOTNOTES |
|---|
This work was supported by National Institutes of Health Grants HL-43178 and DK-38108 and the American Heart Association.
Address for reprint requests and other correspondence: M. Morris, Dept. of Pharmacology and Toxicology, Box 927, Wright State Univ. School of Medicine, Dayton, OH 45401 (E-mail: mariana.morris{at}wright.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 26 May 2000; accepted in final form 15 November 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bains, JS,
and
Ferguson AV.
Nitric oxide depolarizes type II paraventricular neurons in vitro.
Neuroscience
79:
149-159,
1997[Web of Science][Medline].
2.
Burbach, JP,
De Hoop MJ,
Schmale H,
Richter D,
de Kloet ER,
Ten Haaf JA,
and
De Wied D.
Differential responses to osmotic stress of vasopressin-neurophysin mRNA in hypothalamic nuclei.
Neuroendocrinology
39:
582-584,
1984[Web of Science][Medline].
3.
Chen YF and Morris M. Differentiation of brain angiotensin AT1a
and AT1b receptor mRNAs: a specific effect of dehydration. 37:
692-697, 2001.
4.
Coffman, TM.
Gene targeting in physiological investigations: studies of the renin-angiotensin system.
Am J Physiol Renal Physiol
274:
F999-F1005,
1998
5.
Culman, J,
von Heyer C,
Piepenburg B,
Rascher W,
and
Unger T.
Effects of systemic treatment with irbesartan and losartan on central response to angiotensin II in conscious, normotensive rats.
Eur J Pharmacol
367:
255-265,
1999[Web of Science][Medline].
6.
Dawson, CA,
Jhamandas JH,
and
Krukoff TL.
Activation by systemic angiotensin II of neurochemically identified neurons in rat hypothalamic paraventricular nucleus.
J Neuroendocrinol
10:
453-459,
1998[Web of Science][Medline].
7.
Ferguson, AV,
and
Washburn DL.
Angiotensin II: a peptidergic transmitter in central autonomic pathways.
Prog Neurobiol
54:
169-192,
1998[Web of Science][Medline].
8.
Harding, JW,
and
Felix D.
Angiotensin-sensitive neurons in the rat paraventricular nucleus: relative potencies of angiotensin II and angiotensin III.
Brain Res
410:
130-134,
1987[Web of Science][Medline].
9.
Herblin, WF,
Barbara F,
Diamond S,
Gibson SE,
and
Timmermans PB.
A novel angiotensin II binding site in murine tissues.
Life Sci
63:
223-234,
1998[Web of Science][Medline].
10.
Hoffman, GE,
Smith MS,
and
Verbalis JG.
c-Fos and related immediate early gene products as markers of activity in neuroendocrine systems.
Front Neuroendocrinol
14:
173-213,
1993[Web of Science][Medline].
11.
Hohle, S,
Spitznagel H,
Rascher W,
Culman J,
and
Unger T.
Angiotensin AT1 receptor-mediated vasopressin release and drinking are potentiated by an AT2 receptor antagonist.
Eur J Pharmacol
275:
277-282,
1995[Web of Science][Medline].
12.
Ito, M,
Oliverio MI,
Mannon PJ,
Best CF,
Maeda N,
Smithies O,
and
Coffman TM.
Regulation of blood pressure by the type 1A angiotensin II receptor gene.
Proc Natl Acad Sci USA
92:
3521-3525,
1995
13.
Johren, O,
Imboden H,
Hauser W,
Maye I,
Sanvitto GL,
and
Saavedra JM.
Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II subtypes, and vasopressin in the mouse hypothalamus.
Brain Res
757:
218-227,
1997[Web of Science][Medline].
14.
Kihara, M,
Umemura S,
Sumide Y,
Yokoyama N,
Yabana M,
Nyui N,
Tamura K,
Murakami K,
Fukamizu A,
and
Ishii M.
Genetic deficiency of angiotensinogen produces an impaired urine concentrating ability in mice.
Kidney Int
53:
548-555,
1998[Web of Science][Medline].
15.
Krob, HA,
Vinsant SL,
Ferrario CM,
and
Friedman DP.
Angiotensin-(1-7) immunoreactivity in the hypothalamus of the (mRen-2d)27 transgenic rat.
Brain Res
798:
36-45,
1998[Web of Science][Medline].
16.
Larsen, PJ,
and
Mikkelsen JD.
Functional identification of central afferent projections conveying information of acute "stress" to the hypothalamic paraventricular nucleus.
J Neurosci
15:
2609-2627,
1995[Abstract].
17.
Lee, WJ,
Kim KS,
Yang E-K,
Lee JH,
Lee EJ,
Park J-S,
and
Kim H-J.
Effect of brain angiotensin II AT1, AT2, and cholinergic receptor antagonism on drinking in water-deprived rats.
Regul Pept
66:
41-46,
1996[Web of Science][Medline].
18.
Lee, W-J,
Yang E-K,
Ahn D-K,
Park Y-Y,
Park J-S,
and
Kim H-J.
Central ANG II-receptor antagonists impair cardiovascular and vasopressin response to hemorrhage in rats.
Am J Physiol Regulatory Integrative Comp Physiol
268:
R1500-R1506,
1995
19.
Lenkei, Z,
Corvol P,
and
Llorens-Cortes C.
Comparative expression of vasopressin and angiotensin type-I receptor mRNA in rat hypothalamic nuclei: a double in situ hybridization study.
Mol Brain Res
34:
135-142,
1995[Medline].
20.
Li, P,
Morris M,
Diz DI,
Ferrario CM,
Ganten D,
and
Callahan MF.
Role of paraventricular angiotensin AT1 receptors in salt-sensitive hypertension in mRen-2 transgenic rats.
Am J Physiol Regulatory Integrative Comp Physiol
270:
R1178-R1181,
1996
21.
Li, Z,
and
Ferguson AV.
Electrophysiological properties of paraventricular magnocellular neurons in rat brain slices: modulation of IA by angiotensin II.
Neuroscience
71:
133-145,
1996[Web of Science][Medline].
22.
Lind, RW,
Swanson LW,
and
Ganten D.
Organization of angiotensin II immunoreactive cells and fibers in the rat central nervous system.
Neuroendocrinology
40:
2-24,
1985[Web of Science][Medline].
23.
Lu, LM,
Song HY,
and
Yao T.
Effect of angiotensin II on vasopressin gene transcription in the hypothalamus of rats.
Sheng Li Hsueh Pao
47:
373-380,
1995.
24.
Mahon, JM,
Allen M,
Herbert J,
and
Fitzsimons JT.
The association of thirst, sodium appetite and vasopressin release with c-fos expression in the forebrain of the rat after intracerebroventricular injection of angiotensin II, angiotensin-(1-7) or carbachol.
Neuroscience
69:
199-208,
1995[Web of Science][Medline].
25.
Mathai, ML,
Evered MD,
and
McKinley MJ.
Central losartan blocks natriuretic, vasopressin, and pressor responses to central hypertonic NaCl in sheep.
Am J Physiol Regulatory Integrative Comp Physiol
275:
R548-R554,
1998
26.
Moriguchi, A,
Morris M,
Brosnihan KB,
and
Ferrario CM.
Angiotensin-II and angiotensin-(1-7) augment the local release of vasopressin from the paraventricular nucleus (PVN) and the supraoptic nucleus (SON) (Abstract).
Hypertension
21:
587,
1993.
27.
Morris, M,
Li P,
Callahan MF,
Oliverio MI,
Coffman TM,
Bosch SM,
and
Diz DI.
Neuroendocrine effects of dehydration in mice lacking the angiotensin AT1a receptor.
Hypertension
33:
482-486,
1999
28.
Nojiri, H,
Sato M,
and
Urano A.
Increase in the vasopressin mRNA levels in the magnocellular neurosecretory neurons of water-deprived rats: in situ hybridization study with the use of synthetic oligonucleotide probe.
Zool Sci
3:
345-350,
1986.
29.
Ohlstein, EH,
Gellai M,
Brooks DP,
Vickery LJJSA,
Ruffolo RR, Jr,
Weinstock J,
and
Edwards RM.
The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
J Pharmacol Exp Ther
262:
595-601,
1992
30.
Oliverio, MI,
Best CF,
Kim HS,
Arendshorst WJ,
Smithies O,
and
Coffman TM.
Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation.
Am J Physiol Renal Physiol
272:
F515-F520,
1997
31.
Oliverio, MI,
Delnomdedieu M,
Best CF,
Li P,
Morris M,
Callahan MF,
Johnson AK,
Smithies O,
and
Coffman TM.
Abnormal water metabolism in mice lacking the type 1A receptor for ANG II.
Am J Physiol Renal Physiol
278:
F75-F82,
2000
32.
Pastuskovas, C,
and
Vivas L.
Effect of intravenous captopril on c-fos expression induced by sodium depletion in neurons of the lamina terminalis.
Brain Res Bull
44:
236,
1997.
33.
Phillips, MI,
Heininger F,
and
Toffolo S.
The role of brain angiotensin in thirst and AVP release induced by hemorrhage.
Regul Pept
66:
3-11,
1996[Web of Science][Medline].
34.
Qadri, F,
Edling O,
Wolf A,
Gohlke P,
Culman J,
and
Unger T.
Release of angiotensin in the paraventricular nucleus in response to hyperosmotic stimulation in conscious rats: a microdialysis study.
Brain Res
637:
45-49,
1994[Web of Science][Medline].
35.
Qadri, F,
Wolf A,
Waldman T,
Rascher W,
and
Unger T.
Sensitivity of hypothalamic paraventricular nucleus to C- and N-terminal angiotensin fragments: vasopressin release and drinking.
J Neuroendocrinol
10:
275-281,
1998[Web of Science][Medline].
36.
Reis, LC,
Saad WA,
Camargo LA,
Renzi A,
Menani V,
and
Silveira JE.
Inhibitory effect of DUP-753 on the drinking responses of rats to central administration of noradrenaline and angiotensin II and to dehydration.
Braz J Med Biol Res
29:
507-510,
1996[Web of Science][Medline].
37.
Rocha, MJA,
Callahan MF,
Sundberg DK,
and
Morris M.
Sinoaortic denervation alters the molecular and endocrine responses to salt loading.
Neuroendocrinology
57:
729-739,
1993[Web of Science][Medline].
38.
Rowland, NE,
and
Fregly MJ.
Brain angiotensin AT2 receptor antagonism and water intake.
Brain Res Bull
32:
391-394,
1993[Web of Science][Medline].
39.
Sanvitto, GL,
Johren O,
Hauser W,
and
Saavedra JM.
Water deprivation upregulates Ang II AT1 binding and mRNA in rat subfornical organ and anterior pituitary.
Am J Physiol Endocrinol Metab
273:
E156-E163,
1997
40.
Sherman, TG,
McKelvy JF,
and
Watson SJ.
Vasopressin mRNA regulation in individual hypothalamic nuclei: a northern and in situ hybridization analysis.
J Neurosci
6:
1685-1694,
1986[Abstract].
41.
Sugaya, T,
Nishimatsu S,
Tanimoto K,
Takimoto E,
Yamagishi T,
Imamura K,
Goto S,
Imaizumi K,
Hisada Y,
Otsuka A,
Uchida H,
Sugiura M,
Fukuta K,
Fukamizu A,
and
Murakami K.
Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia.
J Biol Chem
270:
18719-18722,
1995
42.
Timmermans, PB,
Wong PC,
Chiu AT,
Herblin WF,
Benfield P,
Carini DJ,
Lee RJ,
Wexler RR,
Saye JA,
and
Smith RD.
Angiotensin II receptors and angiotensin II receptor antagonists.
Pharmacol Rev
45:
205-251,
1993[Web of Science][Medline].
43.
Walters, JK,
and
Hatton GI.
Supraoptic neuronal activity in rats during five days of water deprivation.
Physiol Behav
13:
661-667,
1974[Medline].
44.
Widdop, RE,
Gardiner SM,
and
Bennett T.
Effects of angiotensin II AT1- or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats.
Brain Res
648:
46-52,
1994[Web of Science][Medline].
45.
Windle, RJ,
Forsling ML,
Smith CP,
and
Balment RJ.
Patterns of neurohypophysial hormone release during dehydration in the rat.
J Endocrinol
137:
311-319,
1993
46.
Wright, JW,
Hamilton TA,
and
Harding JW.
Anomalous effects of losartan on aminopeptidase-induced reductions of blood pressure in SHR.
Brain Res Bull
36:
169-174,
1995[Web of Science][Medline].
47.
Wright, JW,
and
Harding JW.
Important role for angiotensin III and IV in the brain renin-angiotensin system.
Brain Res
25:
96-124,
1997[Medline].
48.
Yamaguchi, K,
Hama H,
Sakaguchi T,
Negoro H,
and
Kamoi K.
Effects of intraventricular injection of Sar1-Ala8-angiotensin II on plasma vasopressin level increased by angiotensin II and by water deprivation in conscious rats.
Acta Endocrinol
93:
407-412,
1980.
49.
Yang, E-K,
Lee W-J,
Park Y-Y,
Ahn D-K,
Park J-S,
and
Kim H-J.
Effects of chronic central administration of losartan on the cardiovascular and hormonal responses to hemorrhage in conscious rats.
Regul Pept
67:
107-113,
1996[Web of Science][Medline].
50.
Zingg, HH,
Lefebvre D,
and
Almazan G.
Regulation of vasopressin gene expression in rat hypothalamic neurons. Response to osmotic stimulation.
J Biol Chem
261:
12956-12959,
1986
This article has been cited by other articles:
![]() |
V. Farah, K. M. Elased, and M. Morris Genetic and dietary interactions: role of angiotensin AT1a receptors in response to a high-fructose diet Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1083 - H1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Wichi, V. Farah, Y. Chen, M. C. Irigoyen, and M. Morris Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2007; 292(3): R1184 - R1189. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Elased, D. R. Cool, and M. Morris Novel Mass Spectrometric Methods for Evaluation of Plasma Angiotensin Converting Enzyme 1 and Renin Activity Hypertension, October 1, 2005; 46(4): 953 - 959. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, H. Chen, and M. Morris Enhanced osmotic responsiveness in angiotensin AT1a receptor deficient mice: evidence for a role for AT1b receptors Exp Physiol, September 1, 2005; 90(5): 739 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Rinaman, R. R. Vollmer, J. Karam, D. Phillips, X. Li, and J. A. Amico Dehydration anorexia is attenuated in oxytocin-deficient mice Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1791 - R1799. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, L. F. Joaquim, V. M. Farah, R. B. Wichi, R. Fazan Jr., H. C. Salgado, and M. Morris Cardiovascular autonomic control in mice lacking angiotensin AT1a receptors Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R1071 - R1077. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhou, Y. Chen, W. P. Dirksen, M. Morris, and M. Periasamy AT1b Receptor Predominantly Mediates Contractions in Major Mouse Blood Vessels Circ. Res., November 28, 2003; 93(11): 1089 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Lohmeier Neurohypophysial hormones Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2003; 285(4): R715 - R717. [Full Text] [PDF] |
||||
![]() |
R. L. Davisson Physiological genomic analysis of the brain renin-angiotensin system Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2003; 285(3): R498 - R511. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Skott Body sodium and volume homeostasis Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R14 - R18. [Full Text] [PDF] |
||||
![]() |
J. Kong and Y. C. Li Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R255 - R261. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Skott Angiotensin II and control of sodium and water intake in the mouse Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1380 - R1381. [Full Text] [PDF] |
||||
![]() |
H. Ehmke Mouse gene targeting in cardiovascular physiology Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2003; 284(1): R28 - R30. [Full Text] [PDF] |
||||
![]() |
B. J. A. Janssen and J. F. M. Smits Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1545 - R1564. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |